Associated tags: NOK, AS, Aquaculture, QPS, Heat, Health, Research, Drug development, Neuropharmacology, Biotechnology, Other Science, Fine chemical, Contract research organization, Clinical Trials, Pharmaceutical, Science
Locations: DELAWARE, DEL, EUROPE, ASIA, AUSTRIA, GRAZ
Retrieved on:
Wednesday, January 10, 2024
Health,
Other Science,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
CITES,
Mass spectrometry,
UPLC,
Multimedia,
QPS,
Peptide,
DMPK,
Drug discovery,
LC-MS,
Laboratory,
Therapy,
Doctor of Philosophy,
Biomarker,
HRMS,
Oligonucleotide,
SFC,
Growth,
Fine chemical QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
Key Points:
- QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL).
- View the full release here: https://www.businesswire.com/news/home/20240110198636/en/
Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
- (Photo: Business Wire)
This expansion includes the impressive growth seen in 2023, when QPS installed seven additional UPLC-(HR)MS/MS tandem instruments - four triple quadrupoles, one QTRAP, and two quadrupole time-of-flight high-resolution mass spectrometers (HRMS).
- QPS Subject Matter Experts are some of the best in the industry and this new equipment will provide the capacity for them to expand their relationships with our important biotech and pharmaceutical clients,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
Retrieved on:
Thursday, December 14, 2023
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Health,
Genetics,
Clinical Trials,
Chem,
Tandem mass spectrometry,
QPS,
Chemistry,
GLP,
University of California, Berkeley,
Peptide,
Physikalisch-Technische Bundesanstalt,
Diples,
Multimedia,
Daniel,
LC-MS,
Master of Science,
Therapy,
University of Kassel,
Mass spectrometry,
Drug discovery,
University,
Doctor of Philosophy,
Biomarker,
Oligonucleotide,
UC,
Drug development,
LC-MS/MS,
Fine chemical,
Medtronic,
Bioanalysis QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
Key Points:
- QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
- This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
- This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
- With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.
Health,
Other Science,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Pharmacist,
Administration,
Contract research organization,
Clinical trial,
Hematology,
QPS,
Safety,
Urinalysis,
Multimedia,
Pharmacy,
Physician,
Pharmaceutical industry,
Chemistry,
Serology QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri.
Key Points:
- QPS Holdings, LLC, a global contract research organization has expanded operations in Springfield, Missouri.
- The 2,750-square-foot facility is fully operational as of the fall of 2023 and will give QPS significant flexibility in clinical research study operations.
- View the full release here: https://www.businesswire.com/news/home/20231204471818/en/
QPS Missouri is a division of QPS Holdings, LLC, a global Contract Research Organization.
- QPS Missouri conducts Phase I-IV clinical trials in Springfield, Missouri, and has recently added a new safety laboratory, updated pharmacy, and clinical trial kit production facility.
Retrieved on:
Thursday, November 30, 2023
Research,
Finance,
Neurology,
Clinical Trials,
Professional Services,
Health,
Pharmaceutical,
Other Science,
Science,
CNS,
Sale,
Contract research organization,
Lincoln International,
Acquisition,
Ropes & Gray,
QPS,
KPMG,
Perella Weinberg Partners,
Multimedia,
Neuropharmacology,
DSM-IV codes,
L.E.K. Consulting,
Drug discovery,
CMC,
EY,
Czech Republic,
Drug development,
Pharmaceutical industry,
Nordic Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.
Key Points:
- Today QPS Holdings, LLC (QPS) a leading drug development Contract Research Organization (CRO), announces an agreement to sell its Neuropharmacology business unit (QPS Neuropharmacology) to Scantox, a leading Nordic pre-clinical, GLP-accredited CRO.
- QPS Neuropharmacology, based in Grambach, Austria and focused on drug discovery, specializes in neurodegenerative diseases, rare diseases and mental disorders.
- QPS Neuropharmacology is based in a 2,700 m2 state-of-the-art facility in Grambach, Austria, and employs more than 80 employees.
- We believe that the neuropharmacology unit will be strengthened and continue to grow as part of the Scantox organization” says Ben Chien, President and CEO of QPS Holdings, LLC.
Retrieved on:
Sunday, November 27, 2022
Climate change,
QPS,
Population growth,
EBITDA,
Engineering,
Acquisition,
Natural Resources,
Sewage,
Agriculture,
Urbanization,
Water,
NOK,
Heat,
Aquaculture,
Seawater,
Renewable energy Vienna, November 14, 2022 With the acquisition of QPS AS, Wienerberger is strengthening its market position for water management in the Nordics.
Key Points:
- Vienna, November 14, 2022 With the acquisition of QPS AS, Wienerberger is strengthening its market position for water management in the Nordics.
- This acquisition is yet another step in Wienerbergers strategic development into a full-range system provider for water management, extending the companys footprint in the Nordic market.
- In this segment, Wienerberger supplies a comprehensive portfolio of innovative system solutions for sustainable and efficient water management, which is now broadened through the addition of a complete range of infrastructure pumping stations.
- Climate change, rapid population growth, and urbanization call for new solutions for sustainable water management, says Heimo Scheuch, CEO of Wienerberger.
DMPK,
Research,
Neuropharmacology,
Technology transfer,
Arbutus Biopharma,
Leadership,
FDA,
Regulatory affairs,
Medication,
Toxicology,
QPS,
Clinical trial,
Industry,
Health,
Growth,
Drug development,
GCP,
CRO,
Fine chemical,
Pharma,
Biotechnology QPS LLC expands capabilities in Global Medical Affairs, Regulatory Affairs and Biotech Clinical Research Services.
Key Points:
- QPS LLC expands capabilities in Global Medical Affairs, Regulatory Affairs and Biotech Clinical Research Services.
- Heather Messenger, Sr. Vice President, Head of GlobalBiotech Services, Sarah Cross, Executive Director, Head of Global Medical Affairs and Kimberley Buytaert-Hoefen,Executive Director, Head of Global Regulatory Affairs.
- Ms. Messenger who joins QPS with over 26 years of experience across Biotech, BioPharma and CRO sectors, will be taking the lead in expanding QPS clinical execution services and capabilities, with a focus on Biotech clients.
- These new executives will ensure that QPS has the skills and capabilities to fully implement global Pharma and Biotech drug development projects.
DMPK,
Research,
Neuropharmacology,
Technology transfer,
Sutro Biopharma,
Leadership,
FDA,
Medication,
Toxicology,
QPS,
Clinical trial,
Industry,
Health,
Growth,
Drug development,
GCP,
CRO,
Fine chemical,
Pharma,
Biotechnology With these enhanced global capabilities, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving Biotech's customized needs.
Key Points:
- With these enhanced global capabilities, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving Biotech's customized needs.
- Heather Messenger, Sr. Vice President, Head of GlobalBiotech Services, Sarah Cross, Executive Director, Head of Global Medical Affairs and Kimberley Buytaert-Hoefen,Executive Director, Head of Global Regulatory Affairs.
- Ms. Messenger who joins QPS with over 26 years of experience across Biotech, BioPharma and CRO sectors, will be taking the lead in expanding QPS clinical execution services and capabilities, with a focus on Biotech clients.
- These new executives will ensure that QPS has the skills and capabilities to fully implement global Pharma and Biotech drug development projects.
CNS,
Growth,
CEO,
Patient,
Zoology,
University of Graz,
Central nervous system,
Tetris Holding, LLC v. Xio Interactive, Inc.,
LLC,
Lists of diseases,
Neurodegeneration,
Contract research organization,
QPS,
Quality assurance,
CRO,
Time,
Drug development,
Degenerative disease,
Associate,
Medical device,
Neuropharmacology,
EU NEWARK, Del., Jan. 31, 2022 /PRNewswire/ -- QPS Holdings LLC announced that Dr. Prokesch, currently Associate Director of Neuropharmacology, has been selected as the new Director of Neuropharmacology, assuming the position on January 1, 2022. Prior to her role as Associate Director of Neuropharmacology, Dr. Prokesch served for several years as the Director of Quality Assurance, QPS Austria. As part of her new responsibilities, Dr. Prokesch, who has been a highly valued member of the QPS Austria team since joining in 2001, will partner with Dr. Robert Wronski, Senior Director, Head of EU Late Phase Clinical Development to manage QPS Austria.
Key Points:
- NEWARK, Del., Jan. 31, 2022 /PRNewswire/ --QPS Holdings LLC announced that Dr. Prokesch, currently Associate Director of Neuropharmacology, has been selected as the new Director of Neuropharmacology, assuming the position on January 1, 2022.
- Prior to her role as Associate Director of Neuropharmacology, Dr. Prokesch served for several years as the Director of Quality Assurance, QPS Austria.
- "I am honored to be selected as the next Director of Neuropharmacology at QPS Austria.
- For more information about QPS visit www.qps.com , and for more information about QPS Neuropharmacology, visit www.qpsneuro.com .
CNS,
Growth,
CEO,
Patient,
Zoology,
University of Graz,
Central nervous system,
Tetris Holding, LLC v. Xio Interactive, Inc.,
LLC,
Lists of diseases,
Neurodegeneration,
Contract research organization,
QPS,
Quality assurance,
CRO,
Time,
Drug development,
Degenerative disease,
Associate,
Medical device,
Neuropharmacology,
EU NEWARK, Del., Jan. 31, 2022 /PRNewswire/ --QPS Holdings LLC announced that Dr. Prokesch, currently Associate Director of Neuropharmacology, has been selected as the new Director of Neuropharmacology, assuming the position on January 1, 2022.
Key Points:
- NEWARK, Del., Jan. 31, 2022 /PRNewswire/ --QPS Holdings LLC announced that Dr. Prokesch, currently Associate Director of Neuropharmacology, has been selected as the new Director of Neuropharmacology, assuming the position on January 1, 2022.
- Prior to her role as Associate Director of Neuropharmacology, Dr. Prokesch served for several years as the Director of Quality Assurance, QPS Austria.
- QPS Holdings LLC announced that Dr. Manuela Prokesch has been selected as the new Director of Neuropharmacology
"I am honored to be selected as the next Director of Neuropharmacology at QPS Austria.
- For more information about QPS visit www.qps.com , and for more information about QPS Neuropharmacology, visit www.qpsneuro.com .
NEWARK, Del., June 2, 2021 /PRNewswire/ -- QPS , a GLP/GCP-compliant and CLIA-certified contract research organization (CRO) delivering discovery, preclinical, and clinical drug development services since 1995, was honored with five 2021 CRO Leadership Awards , presented by Clinical Leader and Life Science Leader .
Key Points:
- NEWARK, Del., June 2, 2021 /PRNewswire/ -- QPS , a GLP/GCP-compliant and CLIA-certified contract research organization (CRO) delivering discovery, preclinical, and clinical drug development services since 1995, was honored with five 2021 CRO Leadership Awards , presented by Clinical Leader and Life Science Leader .
- In 2020, QPS received two CRO Leadership Awards, which recognized QPS for excellence in Expertise (Big Pharma) and Reliability (Big Pharma).
- In 2019, QPS also received two CRO Leadership Awards, which recognized QPS for excellence in Reliability (Big Pharma) and Quality (Big Pharma).
- QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services.
